Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/22067
Title: Amoxycillin-clavulanic acid treatment of melioidosis
Authors: Y. Suputtamongkol
D. A.B. Dance
W. Chaowagul
Y. Wattanagoon
V. Wuthiekanun
N. J. White
Mahidol University
Sappasitthiprasong Hospital
Nuffield Department of Clinical Medicine
London School of Hygiene & Tropical Medicine
Keywords: Immunology and Microbiology;Medicine
Issue Date: 1-Jan-1991
Citation: Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.85, No.5 (1991), 672-675
Abstract: Melioidosis is a serious infection with high acute mortality, and a high rate of relapse despite protracted antimicrobial treatment. The current recommended conventional oral treatment regimen is a 4-drug combination of high-dose chloramphenicol, doxycycline and trimethoprim-sulphamethoxazole given for between 6 weeks and 6 months. We have evaluated prospectively the use of amoxycillin-clavulanic acid, to which Pseudomonas pseudomallei is consistently sensitive in vitro, for the oral maintenance treatment of melioidosis. Amoxycillin-clavulanic acid was used either as sole treatment of localized disease, or as maintenance therapy following either parenteral ceftazidime or the conventional 4-drug regime; 20 patients with localized infections and 26 with septicaemic melioidosis received a median of 7·5 (2-12) weeks treatment. After a mean follow-up period of 6 months (range 1-19), 31 patients (67%) remain free of disease. The drug was well tolerated. Three patients had fatal relapses, one other died suddenly at home, and another died from underlying promyelocytic leukaemia. The remaining 10 relapses were treated successfully. Resistance developed in one case. Amoxycillin-clavulanic acid is a safe alternative to the conventional 4-drug antimicrobial combination for the oral treatment of melioidosis. It may be of particular value in children, pregnant women, and in infections with Ps. pseudomallei resistant to the potentially toxic conventional regimen, but the optimum dose and duration of therapy need to be established. © 1991.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0026059406&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/22067
ISSN: 00359203
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.